Medical Advocates
HIV Infection/Disease
  Dyslipidemia  
General Reports
Clinical Management

 




 

 
Adipose Tissue  Main Page   Main New/Newsworthy Home Page  
Last Update: October 11, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader.

General Reports
       

        Journal Papers, Abstracts, and Commentaries

 
Association of APOC3 Polymorphisms with Both Dyslipidemia and Lipoatrophy in
HAART-Receiving Patients.
Bonnet E, Bernard J, Fauvel J, Massip P
AIDS Res Hum Retroviruses. 2008 Feb 1
Abstract
 
Protease Inhibitor-Associated Dyslipidemia in HIV-Infected Patients Is Strongly Influenced by
the APOA5-1131T->C Gene Variation.
 Guardiola M, Ferre R, Salazar J, et al
Clin Chem. 2006 Aug 3;
Abstract
 
Alterations in liver, muscle, and adipose tissue insulin sensitivity in men with HIV
infection and dyslipidemia.
Reeds DN, Yarasheski KE, Fontana L
Am J Physiol Endocrinol Metab. 2005 Aug 23
 Abstract
 
Dyslipidaemia and cardiovascular risk in HIV infection.
 Kulasekaram R, Peters BS, Wierzbicki AS. 
Curr Med Res Opin. 2005 Nov;21(11):1717-25
 Abstract
 
Lipodystrophy and Dyslipidemia Among Patients Taking First-Line, World Health Organization-
Recommended Highly Active Antiretroviral Therapy Regimens in Western India.
Pujari SN, Dravid A, Naik E, et al 
J Acquir Immune Defic Syndr. 2005 Jun 1;39(2):199-202
 Abstract
 
Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy
(HAART) on cardiovascular risk and life expectancy
 Grover SA, Coupal L, Gilmore N, Mukherjee J.
 Am J Cardiol. 2005 Mar 1;9
 Abstract
 
Endoplasmic Reticulum Stress Links Dyslipidemia to Inhibition of Proteasome
Activity and Glucose Transport by HIV Protease Inhibitors.
Parker RA, Flint OP, Mulvey R, et al
 Mol Pharmacol. 2005 Mar 8;
 Abstract
 
Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV
lipodystrophy: a model of 'systemic steatosis'
Balasubramanyam A, Sekhar RV, Jahoor F, et al  
Curr Opin Lipidol. 2004 Feb;15(1):59-67.
 Abstract
 
Cardiovascular Implications of HIV-associated Dyslipidemic Lipodystrophy.
Sekhar RV, Jahoor F, Pownall HJ, et al 
Curr Atheroscler Rep. 2004 May;6(3):173-9.
 Abstract

Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.
Calza L, Manfredi R, Chiodo F.et al 
J Antimicrob Chemother. 2003 Nov 25
Abstract

Alterations in lipid kinetics in men with HIV-dyslipidemia.
Reeds DN, Mittendorfer B, Patterson BW
 Am J Physiol Endocrinol Metab 2003 May 13;
 Abstract

  

        Conference Reports, Abstracts, and Posters

 
Changes in Markers of Atherogenic Dyslipidemia, Inflammation, and Platelet Activation with
Treatment with Pravastatin, Fenofibrate, or the Combination: Results from the ACTG A5087 Team
C Fichtenbaum, TM Yeh, S Evans, et al
(15 CROI)
Abstract
 
Gender and Race/Ethnicity Differences in Dyslipidemia among HIV-infected Patients
Participating in the Fat Redistribution and Metabolic Change Cohort Study
D Wohl, J Currier, R Scherzer, et al
(13 CROI)
Abstract
 
POSTER
The Effect of Polymorphism of the MDR-1 Gene on the Long-term Risk of Lipodystrophy and
Dyslipidemia in HIV-infected Patients Starting ART
A De Luca, S Di Giambenedetto, J Schwarz, et al 
(13 CROI)
PDF Poster     Abstract

Dyslipidemia, Osteopenia, and Changes in Body Habitus in HIV-infected Women
 E Schoenbaum    
(11 CROi)
 Abstract

Dyslipemia and Hyperinsulinemia in HIV Patients on HAART  
 (41 ICAAC)
Abstract

  

Clinical Management
       
        Journal Papers, Abstracts, and Commentaries
 
 
HIV-associated dyslipidaemia: pathogenesis and treatment.
Oh J, Hegele RA 
Lancet Infect Dis. 2007 Dec;7(12):787-96.
 Abstract
 
Treatment of HIV-associated dyslipidemia: a role for omega-3 fatty acids.
Metroka CE, Truong P, Gotto AM Jr.  
AIDS Read. 2007 Jul;17(7):362-4, 367-73.
 Abstract
 
Management of Dyslipidemia and Other Cardiovascular Risk Factors in HIV-Infected Patients:
Case-based Review.
Aberg JA.
Top HIV Med. 2006 Oct-Nov;14(4):134-9.
Abstract
 
Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected
patients with poor response to statins.
Negredo E, Molto J, Puig J, et al  
AIDS. 2006 Nov 14;20(17):2159-2164.
 Abstract
 
Effectiveness and tolerance of atorvastatin for antiretroviral therapy-secondary dyslipemia.
 Soler A, Deig E, Guil J, Rodriguez-Martin M, Guelar A, Pedrol E.
Med Clin (Barc). 2006 Jul 15;127(7):250-2
 Abstract

Exercise training in HIV-1-infected individuals with dyslipidemia and lipodystrophy.
 Terry L, Sprinz E, Stein R, Medeiros NB, Oliveira J, Ribeiro JP. 
Med Sci Sports Exerc. 2006 Mar;38(3):411-7.
 Abstract
 
  Strategies for management and treatment of dyslipidemia in HIV/AIDS.
 Sax PE. 
AIDS Care. 2006 Feb;18(2):149-157
 Abstract
 
  Management of dyslipidemia in patients with complicated metabolic syndrome.
 Davidson MH.  
 Am J Cardiol. 2005 Aug 22;96(4A):22-5.
 Abstract
 
  Treatment of dyslipidaemia in HIV-infected persons.
 Manuel O, Thiebaut R, Darioli R, Tarr PE.
 Expert Opin Pharmacother. 2005 Aug;6(10):1619-45.
Abstract
 
  The role of diet, exercise and smoking in dyslipidaemia in HIV-infected patients with
lipodystrophy.
 Shah M, Tierney K, Adams-Huet B, et al
HIV Med. 2005 Jul;6(4):291-8.
 Abstract
   
  Lipid lowering effects of statins and fibrates in the management of HIV
dyslipidemias associated ith antiretroviral therapy in HIV clinical practice.
 Visnegarwala F, Maldonado M, Sajja P, et al 
J Infect. 2004 Nov;49(4):283-90.
Abstract
 
  Effects of pravastatin on lipoproteins and endothelial function in patients receiving
human immunodeficiency virus protease inhibitors.
 Stein JH, Merwood MA, Bellehumeur JL ,et al.
Am Heart J. 2004 Apr;147(4):713.
 Abstract
 
  Reduction of fat accumulation and lipid disorders by individualized light aerobic
training in human immunodeficiency virus infected patients with lipodystrophy
and/or dyslipidemia.
 Thoni GJ, Fedou C, Brun JF,  et al
 Diabetes Metab 2002 Nov;28(5):397-404
 Abstract
   
  Evaluation and Management of Dyslipidemia in Patients with HIV Infection.
Green ML
J Gen Intern Med 2002 Oct;17(10):797-810
 Abstract
   
  A pilot study of the safety and efficacy of cholestin in treating HIV-related
dyslipidemia.
 Keithley JK, Swanson B, Sha BE, et al.
Nutrition 2002 Feb;18(2):201-204
 Abstract
 
        Conference Reports, Abstracts, and Posters
 
 
Changes in Markers of Atherogenic Dyslipidemia, Inflammation, and Platelet Activation with
Treatment with Pravastatin, Fenofibrate, or the Combination: Results from the ACTG A5087
 Team
C  Fichtenbaum, T M Yeh, S Evans, et al
 (15 CROI)
 Abstract
 
Effect of interventions to improve dyslipidaemia
 M vd Valk, N Friis-Møller, C Sabin, et al
(8th Int Congress on Drug Therapy in HIV Infection)
 Abstract
 
Rosuvastatin in the treatment of dyslipidaemia in HIV patients
 S Das, M Boothby, C Stradling , et al
(8th Int Congress on Drug Therapy in HIV Infection)
 Abstract
 
Dyslipidaemia in an Asian Population following Treatment for 2 Years with 5
Different Protease Inhibitor-containing Regimens: The HIV-NAT Cohort
 C Duncombe , S Kerr , A Avihingsanon, et al
 (12 CROI)
 Abstract
 
Protease Inhibitors, Apolipoprotein C-III Polymorphisms and Atherogenic
Dyslipidemia in HIV
 A Foulkes, D Wohl, P Tebas, et al
 (12 CROI)
 Abstract

Atorvastatin in the treatment of dyslipaemia related to antiretroviral therapy (ART)
 E Pedrol, J Guil, M Rodriguez
(15IAC)
 Abstract

Adipose Tissue  Main Page   Main New/Newsworthy Home Page  

Dyslipidemia